NCT01058590

Brief Summary

Obstructive sleep apnea syndrome (OSAS) is a common disorder in children (2-3%). OSAS in turn, is associated with significant behavioral, learning, and heart problems. Adenotonsillectomy (T\&A, meaning the removal of tonsils and adenoids) is the most common treatment for the problem .Diagnosis of OSAS in children is based on overnight polysomnography (sleep study). Recent studies suggest that upper airway and systemic inflammatory changes exists in school-age children and adults with OSAS, and that anti inflammatory therapy can improve respiratory parameters during sleep and reduce adenoid size, similar to surgery. However, there are no data in the literature on inflammatory changes in infants with the disorder. Healthcare resources utilization, a sensitive marker for diseases is consumed by young children (\<3y) with OSAS more then healthy children, from their first year of life We hypothesize that infants and young children with OSAS present local inflammatory changes of the airways as well as systemic inflammation (in the blood or urine) that contribute to the learning, growing and heart associated medical problems. The Aims of the present study are to characterize the local and systemic inflammatory changes of young children with OSAS, and to evaluate their associated medical problems at diagnosis and after therapy (T\&A) If indeed inflammation is "responsible" for the development of OSAS at such a young age it should be reduced following therapy (i.e. T\&A). In such a case bio-markers may become a part of the algorithms for diagnosis and follow up of such patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2010

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 27, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 28, 2010

Completed
4 days until next milestone

Study Start

First participant enrolled

February 1, 2010

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2012

Completed
Last Updated

January 28, 2010

Status Verified

January 1, 2010

Enrollment Period

1 year

First QC Date

January 27, 2010

Last Update Submit

January 27, 2010

Conditions

Keywords

InflammationAdenotonsillectomy

Outcome Measures

Primary Outcomes (1)

  • Analysis of average change in inflammatory markers, before -to-after T%A.

    February 2011

Eligibility Criteria

Age1 Month - 3 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Children aged 0-3 years diagnosed with obstructive sleep apnea syndrome, refferred to removal of tonsills and adenoids

You may qualify if:

  • Children aged 1 month-3 years
  • Diagnosis of obstructive sleep apnea syndrome(according to a sleep study)

You may not qualify if:

  • Congenital disorders of the respiratory system
  • Congenital craniofacial disorders (retrognathia, Trisomy 21)
  • Use of anti inflammatory medications (like: montelukast, budesonide) up to 4 weeks prior to study entry.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Soroka UMC

Beersheba, 84101, Israel

Location

Related Publications (1)

  • Goldbart AD, Tal A. Inflammation and sleep disordered breathing in children: a state-of-the-art review. Pediatr Pulmonol. 2008 Dec;43(12):1151-60. doi: 10.1002/ppul.20943.

    PMID: 19009600BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum and urine will be obtained before therapy (T%A) snd 3 months afterwards. The serum will be stored at -70 throughout the study in the PI's Lab (DR.Goldbart) At the end of the study the sampled will be assessed for the presence of inflammatory markers (cytokines).

MeSH Terms

Conditions

Sleep Apnea, ObstructiveInflammation

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Aviv D Goldbart, MD

    Soroka UMC

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Aviv D Goldbart, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 27, 2010

First Posted

January 28, 2010

Study Start

February 1, 2010

Primary Completion

February 1, 2011

Study Completion

February 1, 2012

Last Updated

January 28, 2010

Record last verified: 2010-01

Locations